Hypoxia triggers major metabolic changes in AML cells without altering indomethacin-induced TCA cycle deregulation.
Our previous studies have shown that the nonsteroidal anti-inflammatory drug indomethacin exhibits antileukemic activity in vitro and can inhibit the aldo-keto reductase AKR1C3, which we identified as a novel target in acute myeloid leukemia. However, the antileukemic actions of indomethacin are likely to be complex and extend beyond inhibition of either AKR1C3 or cycloxygenases. To further understand the antileukemic activity of indomethacin we have used untargeted nuclear magnetic resonance-based metabolic analysis to characterize the responses of KG1a and K562 cell lines in both normal culture conditions and in hypoxia, which better represents the tumor environment in vivo. Hypoxia induced dramatic metabolic changes in untreated KG1a and K562, including adaptation of both phospholipid and glycolytic metabolism. Despite these changes, both cell lines sustained relatively unaltered mitochondrial respiration. The administration of indomethacin induced similar metabolic responses regardless of the oxygen level in the environment. Notable exceptions included metabolites associated with de novo fatty acid synthesis and choline phospholipid metabolism. Collectively, these results suggest that leukemia cells have the inherent ability to tolerate changes in oxygen tension while maintaining an unaltered mitochondrial respiration. However, the administration of indomethacin significantly increased oxidative stress in both KG1a and K562, inducing mitochondrial dysfunction, regardless of the oxygenation conditions. These findings emphasize the particular pertinence of the tricarboxylic acid cycle to the survival of cancer cells and may explain why some antileukemic drugs have been discovered and developed successfully despite the use of culture conditions that do not reflect the hypoxic environment of cancer cells in vivo.
Lodi
Alessia
A
The Henry Wellcome Building for Biomolecular NMR Spectroscopy, School of Cancer Sciences, Medical School, The University of Birmingham, Edgbaston, Birmingham B15 2TT, U.K.
Tiziani
Stefano
S
Khanim
Farhat L
FL
Drayson
Mark T
MT
Günther
Ulrich L
UL
Bunce
Christopher M
CM
Viant
Mark R
MR
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D015687:Cell Hypoxia; D045744:Cell Line, Tumor; D002952:Citric Acid Cycle / Q000187:drug effects*; D006019:Glycolysis / Q000187:drug effects; D006801:Humans; D000860:Hypoxia / Q000378:metabolism*; D007213:Indomethacin / Q000494:pharmacology*; D015470:Leukemia, Myeloid, Acute / Q000378:metabolism* / Q000473:pathology; D009682:Magnetic Resonance Spectroscopy; D008928:Mitochondria / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects; D010100:Oxygen / Q000378:metabolism*; D010743:Phospholipids / Q000378:metabolism
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010743:Phospholipids; D010100:Oxygen; D007213:Indomethacin